NOMADS UAB, Lithuania, Receives a Research Grant from Lithuanian Business Support Agency LVPA

NOMADS UAB, Vilnius, Lithuania (“NOMADS”), a wholly owned subsidiary of Nomad Bioscience GmbH, Munich, Germany, is pleased to announce that the Company has been awarded a research grant from LVPA (Lietuvos Verslo Paramos Agentūra, Lithuanian Business Support Agency) to extend its exploration of antibacterial proteins for control of multi-drug and pan-drug resistant pathogenic bacteria Klebsiella and Pseudomonas.

The grant covers multiple areas of research and early development of product candidates in NOMADS’ R&D pipeline, including, but not limited to, generation of different chimeric novel bacteriocins as well as in vitro and in vivo preclinical studies of the molecules. The grant provides NOMADS with access to external contract research organizations.

“We are very pleased that NOMADS was able to secure a grant in a highly competitive bidding process“, said Prof. Jurijus Gleba, Nomad’s CEO. “It will add additional EUR 0.85 million to NOMADS’ research budget over the next two years. The total amount of secured support from the Government in previous and current grants to NOMADS now reached over EUR 2.2 million. We are grateful to Lithuanian government authorities for their strategic efforts to support high-tech, in particular biotech start-ups and young companies. High quality of the research at NOMADS is reflected in the registration of their first product as GRAS in USA, filing several important patents and publications in the best peer reviewed journals. NOMADS and its parent company Nomad are among few companies developing antibacterials of entirely new classes, and we intend to aggressively develop our products and bring them to the market promptly through partnerships with strategic partners.”


Nomads UAB is a biotechnology company developing new non-antibiotic antibacterials, including bacteriocins and phage endolysins, to be used as pharmaceuticals, food additives and medical devices. Current emphasis of NOMADS is control of multi-drug and pan-drug resistant Gram-negative bacteria such as Klebsiella and Pseudomonas.
Contact info:

Über die Nomad Bioscience GmbH

Nomad Bioscience, headquartered in Munich/Halle, Germany, is a private biotechnology company developing plant-made biopharmaceuticals, food additives, biomaterials and agronomic traits that address critical unmet needs. Nomad’s plant-based transient protein expression technologies are licensed to several companies for a broad range of products. Nomad’s product pipeline consists of several selected protein candidates for human and animal health, food safety and taste modification, and it includes plant-made antimicrobial proteins (colicins, other bacteriocins and phage lysins), antiviral proteins (griffithsin and other lectins), as well as taste modifying proteins including thaumatins.

The Company is actively seeking corporate partners to help develop and commercialize its products.

Firmenkontakt und Herausgeber der Meldung:

Nomad Bioscience GmbH
Weinbergweg 22
06120 München
Telefon: +49 (345) 1314-2600

Yuri Y. Gleba
Telefon: +49 (345) 1314-2424
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.